Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | AVZO-023 + Letrozole |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| AVZO-023 | AVZO023|AVZO 023|ARTS023|ARTS 023|ARTS-023 | CDK4 Inhibitor 18 | AVZO-023 (ARTS-023) inhibits CDK4, which potentially induces growth arrest and decreases tumor growth (Cancer Res (2025) 85 (8_Supplement_1): 3026). | |
| Letrozole | Femara | Letrozol | Aromatase Inhibitor 3 | Femara (letrozole) is an aromatase inhibitor, which inhibits estrogen synthesis, and is approved for postmenopausal women with hormone receptor positive breast cancer (FDA.gov). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06998407 | Phase Ib/II | AVZO-023 + Fulvestrant ARTS-021 + AVZO-023 + Fulvestrant ARTS-021 + AVZO-023 + Letrozole AVZO-023 + Letrozole | Study of AVZO-023 as a Single Agent and in Combination With AVZO-021, and/or Endocrine Therapy in Advanced Solid Tumors | Recruiting | USA | 0 |